<DOC>
	<DOCNO>NCT00103649</DOCNO>
	<brief_summary>The purpose study assess xaliproden 's potential capacity slow deterioration cognitive global function patient mild moderate Alzheimer 's disease . The patient participate study take orally daily xaliproden placebo ( inactive substance pill ) .</brief_summary>
	<brief_title>18-Month Study Efficacy Xaliproden ( SR57746A ) Patients With Mild-to-Moderate Dementia Alzheimer 's Type</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<criteria>Diagnosis probable Alzheimer 's disease use NINCDSADRDA criterion Mild moderate degree severity dementia assess MiniMental State Examination score 16 26 ( inclusive ) Potential participant may treat conventional Alzheimer 's disease therapy must stable dose least 6 month prior randomization entire study period Potential participant must reliable caregiver must live community assist live facility Mother tongue English , Spanish French ( oral write fluency ) Signed informed consent potential participant legal representative identify caregiver Potential participant cause dementia . Potential participant serious health problem Alzheimer 's disease Use investigational drug within two month prior randomization study</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2008</verification_date>
</DOC>